← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Mayo Clinic Jacksonville (A Nonprofit Corporation)
$61,371,918
Total funding
40
Grants
Funding over time
peak $16.9M · FY2008–25$20M$15M$10M$5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$60,000,751 · 38
NASA$1,371,167 · 2
By mechanism
—$61,371,918 · 40
Investigators at Mayo Clinic Jacksonville (A Nonprofit Corporation)
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
FOLATE RECEPTOR ALPHA VACCINES FOR PREVENTING PROGRESSION OF TNBC FOLLOWING FIRST-LINE CONVENTIONAL THERAPY$8,497,233
· FY2015 · Defense Health Agency
FOLATE RECEPTOR ALPHA VACCINES FOR PREVENTING PROGRESSION OF TNBC FOLLOWING FIRST-LINE CONVENTIONAL THERAPY$6,595,285
· FY2015 · Defense Health Agency
COMBINATION TRASTUZUMAB AND VACCINE THERAPY TO PREVENT DISEASE RECURRENCE IN LOCALLY ADVANCED HER2+ BREAST CANCER$5,977,098
· FY2018 · Defense Health Agency
COMBINATION TRASTUZUMAB AND VACCINE THERAPY TO PREVENT DISEASE RECURRENCE IN LOCALLY ADVANCED HER2+ BREAST CANCER$5,549,747
· FY2018 · Defense Health Agency
THE INCLUSIVE CANCER CARE RESEARCH EQUITY (ICCARE) FOR BLACK MEN CONSORTIUM$4,623,272
· FY2024 · Defense Health Agency
PHASE 1 CLINICAL TRIAL OF A NOVEL HER2 VACCINE FOR PATIENTS WITH DCIS$2,914,678
· FY2016 · Defense Health Agency
ESTABLISHMENT OF AN INCLUSIVE CANCER CARE RESEARCH EQUITY (ICCARE) FOR BLACK MEN CONSORTIUM$2,024,412
· FY2022 · Defense Health Agency
TARGETING TRYPSIN-INFLAMMATION AXIS FOR PANCREATITIS THERAPY IN A HUMANIZED PANCREATITIS MODEL$1,787,667
· FY2015 · Department of the Army
CHARACTERIZATION OF TRPC6 TO PREDICT AND PREVENT CHEMOTHERAPY-RELATED CARDIOMYOPATHY AND HEART FAILURE IN WOMEN$1,770,360
· FY2022 · Department of the Army
INHIBITORS OF RDP-43 AGGREGATION AN DTOXICITY$1,377,000
· FY2010 · Department of the Army
FEASIBILITY OF ESTABLISHING COMMUNITY LIVING LABS TO IMPROVE ACCESS TO PROSTATE HEALTH RESOURCE, EDUCATION, AMENITIES, AND COMMUNITY HEALTH (REACH) FOR BLACK MEN$1,190,974
· FY2025 · Defense Health Agency
RESOLVING THE CRITICAL ROLE OF PINK1 EXPRESSION AND ACTIVITY IN PARKINSON'S DISEASE PATHOPHYSIOLOGY AND THERAPEUTIC INTERVENTION$1,186,914
· FY2025 · Defense Health Agency
EARLY-ONSET PARKINSON'S DISEASE IS A MITOCHONDRIAL DISEASE: A NIGRAL MITOCHONDRIAL CYTOPATHY$1,176,917
· FY2017 · Department of the Army
EARLY-ONSET PARKINSON'S DISEASE IS A MITOCHONDRIAL DISEASE: A NIGRAL MITOCHONDRIAL CYTOPATHY$1,150,197
· FY2017 · Department of the Army
OVERRIDING RADIATION THERAPY RESISTANCE AND ENHANCING FHE ABSCOPAL EFFECT IN RENAL CANCER.$1,134,572
· FY2021 · Defense Health Agency
SPECIFICALLY WE POSTULATE THAT MICROGRAVITY MAY DECREASE MSC NUMBER AND DISTURB THE SECRETION OF TROPHIC FACTORS THAT IMPEDE BONE HOMEOSTASIS BY REDUCING NEW BONE FORMATION AND/OR INCREASING BONE RESORPTION IN MICROGRAVITY.$1,090,755
· FY2021 · National Aeronautics and Space Administration
EPIGENETIC REGULATION OF THE IMMUNE SYNAPSE IN MELANOMA$988,016
· FY2022 · Defense Health Agency
TDP-43, AGGREGATION AND CELLULAR TOXICITY$918,000
· FY2009 · Department of the Army
CHARACTERIZATION OF TRPC6 TO PREDICT AND PREVENT CHEMOTHERAPY-RELATED CARDIOMYOPATHY AND HEART FAILURE IN WOMEN$874,988
· FY2022 · Department of the Army
RESOLVING THE CRITICAL ROLE OF PINK1 EXPRESSION AND ACTIVITY IN PARKINSON'S DISEASE PATHOPHYSIOLOGY AND THERAPEUTIC INTERVENTION$813,085
· FY2025 · Defense Health Agency